GLP's
Retatrutide + Cagrilintide
30 mg + 10 mg
Triple agonist research peptide (GIP / GLP-1 / glucagon)
Composition
Retatrutide 30 mg, Cagrilintide 10 mg
Research overview
Retatrutide is an investigational multi-receptor agonist studied in metabolic research for interactions with GIP, GLP-1, and glucagon pathways. Published human studies and newer late-stage trial updates focus on body weight, glycemic markers, cardiometabolic endpoints, and tolerability.
Potential research areas
- GIP / GLP-1 / glucagon signaling
- Metabolic research models
- Appetite and energy-balance pathways
- Body-composition endpoints
Research profile
Retatrutide, identified in the literature as LY3437943, is an investigational peptide reported to act at three receptors: GIP, GLP-1 and glucagon. Phase 2 trials have reported body-weight and glycaemic endpoints. It holds no marketing authorisation from any regulator.
Read the full Retatrutide profile →- Form
- Lyophilized Powder
- Category
- Research Peptide
- Use
- Research Only
Current evidence varies by compound. Many products discussed in this guide remain investigational, are not approved for general clinical use, and should only be handled under qualified research protocols.
No dosing, administration, or treatment instructions are provided.